This Thematic Series reports the latest results on advanced and integrated solutions for tumor visualization and therapy based on nanomaterials. The main focus is novel solutions and nanomaterials that enhance anticancer therapy efficacy and reduce health care costs at the hospital. The integration of novel nanoparticles (nanosilicon, metal oxides, upconverting, carbon-based) into the pre-clinical/clinical environment has the potential to yield highly efficient and cost-effective cancer theranostics. Topics covered in this Thematic Series include:
Figure 1: UV–vis absorption spectra of (a) silver nanoparticles with an absorption band at 415 nm and (b) sol...
Figure 2: (a) Scanning electron microscopy (SEM) image of silver nanoparticles. The nanoparticles have a high...
Figure 3: Preprocessed mean SERS spectra and standard deviations of the different cell lines. Labeled bands a...
Figure 4: First four principal components used for the support vector machine model. These loadings represent...
Figure 5: Score values of first four principal components of different cell lines. The four cell lines, MCF-7...
Figure 1: The concentration-dependent effect of QDs on the viability of MSCs. Viability was measured by a col...
Figure 2: Evaluation of the optimal QD uptake conditions in skin MSCs. Time-dependent (a) and concentration-d...
Figure 3: The release of QDs from MSCs. (a) QD loss in complete medium (FBS +) and serum-free medium (FBS −) ...
Figure 4: Representative data on the impact of QDs on immunophenotype and proliferation of MSCs. (a) Characte...
Figure 5: Differentiation of MSCs into adipocytes, chondrocytes and osteocytes. Oil Red O staining of cells i...
Figure 6: Quantification of osteogenesis and chondrogenesis in MSCs. Absorbance of Alizarin Red S (a) and Alc...
Figure 7: QD endocytic pathway in MSCs. QD uptake pathway in MSCs labelled with QDs in complete medium (a) or...
Figure 8: QD co-localization with endosomal compartments. Three overlaid channels represent the nucleus (blue...
Figure 1: Particle size of blank and drug-loaded nanoparticles (n = 3, ± SD).
Figure 2: Zeta potential of blank and drug-loaded nanoparticles (n = 3, ± SD).
Figure 3: Mean particle diameter of nanoparticle formulations over the course of 30 days (n = 3, ± SD).
Figure 4: Docetaxel encapsulation efficiency of nanoparticle formulations (n = 3, ± SD).
Figure 5: Cumulative release profile of DOC from nanoparticles (a) and nanoparticulate DOC from HpC films (b)...
Figure 6: Cell viability of blank nanoparticles for 24 and 48 h (n = 3, ± SD).
Figure 7: RG2 cell viability with blank and DOC-loaded nanoparticles for 24 and 48 h (n = 3, ± SD).
Figure 1: Schematic representation of amphiphilic 6OCaproβCD (a), amphiphilic PC βCDC6 (b), chitosan (c) and ...
Figure 2: Time-dependent variation of particle size (nm) of PCX-loaded amphiphilic CD nanoparticles stored in...
Figure 3: Time-dependent variation of the PDI value of PCX-loaded amphiphilic CD nanoparticles stored in aque...
Figure 4: Time-dependent variation of the zeta potential value of PCX-loaded amphiphilic CD nanoparticles sto...
Figure 5: Cumulative release profile of PCX from different amphiphilic CD nanoparticles at pH 7.4 phosphate b...
Figure 6: Cytotoxicity of unloaded amphiphilic CD nanoparticles on L929 mouse fibroblast cell line with MTT a...
Figure 7: IC50 value of PCX solution in DMSO on MCF-7 human breast cancer cell line (n = 3, ± SD).
Figure 8: Anticancer activity of PCX-loaded amphiphilic CD nanoparticle formulations and PCX solution in DMSO...
Figure 1: DLS measurement of the CaF2:(Tb3+,Gd3+) NPs (number- and volume-weighted). Inset: TEM micrograph of...
Figure 2: In the upper part, the XRD pattern of the CaF2:(Tb3+,Gd3+) NPs (d = 5–10 nm, doping concentration o...
Figure 3: Normalized photoluminescence spectrum of CaF2:(Tb3+,Gd3+) NPs at an excitation wavelength of λexc =...
Figure 4: a) T1-weighted MR image of the CaF2:(Tb3+,Gd3+) NPs with different concentrations in the range from...
Figure 5: Relaxivity values of the four batches as prepared (green) and nine months (grey) after fabrication....
Figure 6: Sedimentation study of the CaF2:(Tb3+,Gd3+) NPs (5 mg·mL−1) in Dulbecco’s Modified Eagle’s Medium (...
Figure 7: a) Representative microscopic image of hdF 24 h after treatment with the NPs (c = 1 mg·mL−1). b) Ce...
Figure 1: DLS (hydrodynamic size) results of C60FAS (grey; concentration 0.15 mg/mL) and C60+Cis mixture (red...
Figure 2: AFM images of a) nanoparticles in C60FAS (concentration 0.15 mg/mL) and b) C60+Cis mixture (molar r...
Figure 3: The calculated energy-optimized structure of the C60+Cis nanocomplex in aqueous solution.
Figure 4: The representative comet-assay images obtained after 20 min of electrophoresis of a) control cells,...
Figure 5: The relative amount of DNA in the comet tails (P) after 20 min of electrophoresis of a) lymphocytes...
Figure 6: C60 fullerene, Cis and their nanocomplex induce apoptosis as well as necrosis of lymphocytes from h...
Figure 1: Scanning electron microscopic images of blank (A) and NO550-loaded (B) polymeric microspheres.
Figure 2: NO-releasing sodium nitroprusside (SNP) leads to light emission of NO550-loaded microspheres. Confo...
Figure 3: NO550-loaded microspheres detect the inflammatory response of murine macrophage-like RAW 264.7 cell...
Figure 4: Quantification of NO release with NO550-loaded microspheres in inflamed cells. LPS-stimulated murin...
Figure 1: a) TEM image of cobalt ferrite NPs synthesized hydrothermally in a solution containing 25.0 mmol·L−1...
Figure 2: HRTEM image of CoFe2O4@Met NPs after sonication in 15 mmol·L−1 HAuCl4 solution at 37 °C for 4 h (a)...
Figure 3: Absorption spectra of methionine (1), tetrachlorauric acid (2) and reddish-pink colored solution of...
Figure 4: a) AFM 3D image and b) size distribution histogram b) of Au species removed from the surface of CoFe...
Figure 5: Deconvoluted X-ray photoelectron spectrum (XPS) of Au 4f.
Figure 6: FTIR spectra of methionine (a, a′), methionine sulfoxide (b, b′), cobalt ferrite NPs stabilized wit...
Figure 1: SEM images of the core NaGdF4:Yb,Er (A) and core@shell NaGdF4:Yb,Er@NaGdF4 (B) nanoparticles. The i...
Figure 2: XRD pattern of NaGdF4:Yb,Er core only (a), and NaGdF4:Yb,Er@NaGdF4 core–shell (b) nanoparticles.
Figure 3: The structure of (a) oleic acid (OA) and (b) Tween 80. FTIR spectra of (c) pure Tween 80, (d) NaGdF4...
Figure 4: (a) Upconversion luminescence spectra of Tween 80-coated UCNPs upon 980 nm excitation [28] and (b) ener...
Figure 5: Magnetic resonance (MR) signal intensity (SI) plot of core (red dots) and core–shell (black squares...
Figure 6: A) Confocal images of MDA-MB-231 cells after 24 h treatment with Tween 80-coated core–shell UCNPs (...
Figure 7: Formation of water-soluble core and core–shell UCNPs by coating with Tween 80.
Figure 1: Key steps for addressing cervical cancer as public health concern. New optical technologies and inn...
Figure 2: Cross-section of uterus and vagina; schematics of cervical intraepithelial neoplasia development.
Figure 3: Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. Adapted from [22].
Figure 4: Diffuse reflectance and/or fluorescence spectroscopy for the optical analysis of tissue; λ is a wav...
Figure 5: Reflectance colposcopic images (a) before and (b) after application of acetic acid; (c) reconstruct...
Figure 6: Site-to-site variations in fluorescence spectra measured at different pathologically confirmed (a) ...
Figure 7: Raman vibrational spectroscopy for probing the molecular chemical bonds as well as crystal lattice ...
Figure 8: Cervical epithelium examined using (i) colposcopy, (ii) confocal endomicroscopy and (iii) conventio...
Figure 9: Illustration of optical molecular-targeted imaging with nanoparticles.
Figure 10: Polarimetric images of a cervical specimen taken at 550 nm: (a) depolarization (b) scalar retardanc...
Figure 11: (a) Histological map (colored lines) superimposed on an RGB image of a conization sample; HPV: epit...
Figure 12: (a) OCT image of normal cervical tissue (BM: basement membrane, EP: epithelium, ST: stroma); (b) OC...